98%
921
2 minutes
20
Introduction: Guideline-driven de-escalation of the extent of surgery for low-risk thyroid cancer has made treatment decisions more complex. Shared decision-making (SDM) is more involved than informed consent, improves patient satisfaction, and is considered standard of care. Patient decision aids (DA) can facilitate SDM but appropriate resources are lacking.
Methods: DA development occurred in 3 main phases. First, a prototype DA was developed and refined by a working group (clinicians, behavioral scientists, nurses, and trained consumer). Nationwide clinician consultation sessions obtained mixed-methods feedback leading to a hybrid paper-web DA ready for patient testing. Second, the paper DA was used within clinically appropriate consultations (Bethesda 3-6 thyroid nodules) and patient feedback obtained with the Ottawa acceptability and decisional conflict scales. Three cycles of iterative changes were made to the DA. Patient focus groups led to further refinements. Third, 40 clinicians were invited to review DA materials, providing mixed-methods feedback.
Results: Initial clinician consultation sessions (n = 113) revealed that surgeons used information resources more frequently in, and were more satisfied with, their current patient discussions around thyroid cancer management compared with endocrinologists (88% vs. 32% and 95% vs. 46% respectively, p < 0.01 for both). 95% of clinicians were open to using the DA, but concerns regarding availability, appropriateness, flexibility, credibility and potential to lengthen consultations, were raised. Patients reported that the DA was useful (97% paper, 100% web) and sufficient (85% paper, 100% web). Decisional conflict was low (17 paper vs. 12 web). Qualitative feedback led to changes to improve visual appeal, readability and minimize emotive responses. Clinician review of DA (60% response) reported no bias (73% paper, 79% web) and 86% felt the DA would be easily incorporated into practice.
Conclusion: We present a hybrid paper and web-DA ready for wider testing in patients with low-risk thyroid cancer to complement SDM regarding the extent of surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/wjs.70064 | DOI Listing |
Head Neck Pathol
September 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Myoepithelial carcinoma (MECA) is a malignant neoplasm composed exclusively of myoepithelial cells and accounts for less than 1% of all salivary gland tumors. Its diagnosis is often challenging due to histologic overlaps with benign lesions and its variable morphologic presentation. Although molecular profiling has emerged as a valuable tool in salivary gland tumor classification, the genetic landscape of MECA remains incompletely defined.
View Article and Find Full Text PDFInt J Surg
September 2025
BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Thyroid cancer, a prevalent endocrine malignancy, is influenced by its tumor microenvironment (TME), with cancer-associated fibroblasts (CAFs) playing a pivotal role in disease progression. Molecularly, CAFs orchestrate a pro-tumorigenic niche via cytokine secretion and extracellular matrix (ECM) stiffening, underscoring their targetability. Therapeutic strategies, including small molecule inhibitor-based therapies, immune-based therapies, nanoparticle-based approaches, and combination regimens, have been evaluated for their efficacy in disrupting CAF functionality.
View Article and Find Full Text PDFFood Sci Nutr
September 2025
Department of Thyroid and Breast Surgery, Oncological Surgery The Third Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
Triple-negative breast cancer (TNBC) is an aggressive and challenging subtype of breast cancer, presenting patients with a more complex treatment journey. This underscores the critical need for ongoing research and the development of effective therapies to enhance patient outcomes. Signal transducer and activator of transcription 3 (STAT3) is a crucial transcription factor that regulates various cellular processes, including proliferation, survival, and immune modulation.
View Article and Find Full Text PDFData Brief
October 2025
Department of Endocrinology, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
This dataset focuses on N6-Methyladenosine (m6A) RNA methylation in papillary thyroid carcinoma (PTC) without autoimmune thyroid disease (AITD). Emerging evidence suggests that m6A modification was associated with the occurrence and progression of both thyroid carcinoma and AITD. Given the substantial clinical overlap between thyroid carcinoma (particularly PTC) and AITD, rigorous exclusion of autoimmune confounding factors is essential to isolate the distinct role of m6A modifications in driving thyroid carcinogenesis and progression.
View Article and Find Full Text PDFFront Cell Dev Biol
August 2025
Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Thyroid carcinoma is among the most common endocrine system malignancies. Lactate metabolism and lactylation modification roles in carcinogenesis and development have garnered more interest in recent years. The expression and function of lactate transporters (MCTs) and significant metabolic enzymes are included in our summary of the characterisation of lactate metabolism in thyroid cancer.
View Article and Find Full Text PDF